April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Treatment for Endophthalmitis: Pathogens, Antibiotics, and Final Visual Acuity
Author Affiliations & Notes
  • S. D. Cassard
    Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland
  • E. W. Gower
    Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland
  • D. E. Stare
    Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland
  • J. M. Tielsch
    International Health, Johns Hopkins School of Public Health, Baltimore, Maryland
  • O. D. Schein
    Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland
  • Footnotes
    Commercial Relationships  S.D. Cassard, None; E.W. Gower, None; D.E. Stare, None; J.M. Tielsch, None; O.D. Schein, None.
  • Footnotes
    Support  NEI R01 EY16769
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 2513. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. D. Cassard, E. W. Gower, D. E. Stare, J. M. Tielsch, O. D. Schein; Treatment for Endophthalmitis: Pathogens, Antibiotics, and Final Visual Acuity. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2513.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Endophthalmitis is a relatively rare but severe infection that can occur following cataract surgery. We report population-based results related to pathogens and treatment patterns.

Methods: : Post-cataract surgery endophthalmitis cases were identified using 2003-2004 Medicare billing claims. Cases were then limited to individuals diagnosed in California, Florida, Illinois, Michigan and Texas. Treating physicians were contacted via telephone and requested to complete a questionnaire on clinical and microbiological data and to submit any relevant chart information. Materials were reviewed by two independent observers for confirmation of culture proven endophthalmitis.

Results: : 507 cases of presumed endophthalmitis were confirmed. Among these, 447 (88%) had culture results available, and 268 (60%) of this subset were culture positive. 92% cultured gram-positive organisms, and 16 specimens cultured MRSA. 3 fungal cases were reported.The distribution of pathogens differed by age group. Among the 85+ age group, MRSA accounted for 15% of organisms versus 5% in the younger populations (p=.04). MRSA was more common among non-whites, accounting for 14% of all culture positive organisms compared to 5% within the white population (p=0.08). No differences in pathogen distribution were seen between men and women.Presenting visual acuity was 20/200 or worse for 92% of culture positive cases and for 79% of culture negative cases (p=0.0002). Culture positive compared to culture negative cases were more likely to undergo vitrectomy (64% vs. 44%, respectively; p<0.0001). 99% of both culture positive and culture negative cases received intravitreal vancomycin, usually in combination with ceftazidime (70%), amikacin (22%) or another antibiotic. 25% also received a systemic antibiotic. Final visual acuity was 20/200 or worse for 40% of culture positive cases compared to 29% of culture negative cases (p=0.02). Among culture positive cases, those treated with intravitreal vancomycin and amikacin were less likely to have poor visual acuity (20/200 or worse) at follow-up compared to other regimens (p=0.06).

Conclusions: : Intravitreal injection with vancomycin, combined with either ceftazidime or amikacin, is the most common treatment regimen for post-cataract surgery endophthalmitis. Culture positive cases had poorer visual outcomes compared to culture negative cases. A trend towards better visual outcomes was found for culture positive cases treated with vancomycin combined with amikacin.

Keywords: cataract • endophthalmitis • clinical (human) or epidemiologic studies: outcomes/complications 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×